Revolutionary NHS AI Blood Test May Minimize Invasive Tests for Womb Cancer Detection

The landscape of cancer diagnostics is evolving, with several NHS hospitals in England gearing up to implement an AI-powered blood test designed to help assess women potentially at risk of womb cancer. This innovative approach aims to streamline patient care by providing preliminary assessments prior to invasive procedures.

The Importance of Early Assessment

In England, approximately 90,000 postmenopausal women are referred by GPs each year due to heavy bleeding—a primary symptom that can lead to worries about womb cancer. Alarmingly, out of these, about 10,000 women receive a diagnosis of womb cancer annually, with around 2,700 succumbing to the disease. The introduction of the AI-powered blood test is crucial in changing these staggering statistics.

How the PinPoint Test Works

Developed by Leeds-based PinPoint Data Science, the PinPoint Test employs machine learning algorithms to evaluate cancer risk based on an analysis of blood markers. It assesses approximately 30 different markers, classifying patients into three risk categories: low, elevated, or high. Priced at around £30, the test generates a risk score that can assist healthcare professionals in deciding the appropriate follow-up steps—whether that means monitoring the patient, referring them for further investigation, or expediting their assessment.

PinPoint touts this test as a multi-cancer tool, already making strides in pathways related to various cancers, including gynaecological, lung, and upper gastrointestinal cancers. Following a thorough trial that encompassed 16,481 patients referred through urgent suspected cancer pathways in Yorkshire, the results showed compelling outcomes—about one in ten women referred for heavy bleeding were found to have cancer.

Impressively, the PinPoint Test identified 99.1% of cancers as elevated or high risk, delivering a remarkable negative predictive value of 99.8% for women considered low risk. This means that it can effectively rule out cancer in women within the lowest-risk group, providing peace of mind and reducing unnecessary invasive procedures.

Impact on Existing Diagnostic Pathway

Currently, women referred for suspected reproductive system cancers typically undergo a pelvic examination, which includes a transvaginal ultrasound. This procedure, while essential, can be uncomfortable or even painful for many women. If suspicion of cancer remains, further testing, including biopsies and hysteroscopies, might be required. The PinPoint Test is designed to intervene early, potentially eliminating the necessity for many women to undergo such invasive checks.

By identifying low-risk patients beforehand, PinPoint estimates that around 18,000 women annually in England could avoid the discomfort of transvaginal ultrasound scans. This change could significantly enhance the patient experience by alleviating anxiety and streamlining care pathways.

Expert Voices on the Test

Professor Sean Duffy, chief medical officer at PinPoint Data Science, emphasizes that the test’s greatest value lies in accurately ruling out women at very low risk, thus conserving valuable healthcare resources. Dr. Jacinta Walsh, a GP from West Yorkshire, noted that the current system can require numerous GP visits to ensure cancer is ruled out. The introduction of this test has the potential to shorten this tedious process, allowing for quicker assessments and freeing up capacity for other patients.

Consultant gynaecologist Tracy Jackson from Leeds Teaching Hospitals NHS Trust expressed optimism regarding the test’s potential. She observed that most women referred for investigations do not actually have cancer, and the current diagnostic procedures can be distressing and uncomfortable. The PinPoint Test could serve as a vital triage tool, enabling clinicians to prioritize higher-risk patients for further checks while ruling out those who are low risk right in primary care.

Other NHS AI Deployments

The NHS is increasingly embracing AI technologies beyond just the PinPoint Test. Recently, the MEMORI system has been deployed at Kent and Canterbury Hospital for assessing infection risks based on routine patient data. Furthermore, an AI triage tool integrated within the NHS App is set to reach over 200,000 patients within the next year, highlighting the growing role of AI in healthcare.

Moreover, the government has allocated £20 million towards rolling out AI-powered tools for chest X-rays, aiming to reach all NHS trusts in England by 2029. These advancements reflect a broader commitment to leveraging AI for improved diagnostic outcomes, with a particular focus on cancer care and early detection.

While the PinPoint Test represents a promising step forward, Cancer Research UK has noted that more research is essential to fully understand its implications on patient outcomes, overall referral decisions, and the NHS’s diagnostic capacity. Samantha Harrison from the charity asserted that early detection can save lives, yet patients are frequently not diagnosed promptly enough. The PinPoint Test may provide an innovative solution by helping to rule out endometrial cancer swiftly and efficiently.

(Photo by Adam Mills)

Want to learn more about AI and big data from industry leaders? Check out AI & Big Data Expo taking place in Amsterdam, California, and London. The comprehensive event is part of TechEx and is co-located with other leading technology events—click here for more information.

AI News is powered by TechForge Media. Explore other upcoming enterprise technology events and webinars here.